BSEM Earnings Date & History
Biostem Technologies Inc (OTC MARKETS) earnings schedule, consensus estimates and reported results for the last eight quarters.
Last updated Aug 19, 2026 at 7:34 PM ET
Biostem Technologies Inc
Pharmaceuticals
- Next earnings date
- Wednesday, November 11, 2026
- Reporting session
- Time TBD
- EPS estimate
- $-0.47
- Revenue estimate
- $8.1M
BSEM earnings history
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| Wednesday, August 12, 2026 | Q2 2026 | $-0.51 | $-0.52 | -2.0% | $7.9M |
| Thursday, May 14, 2026 | Q1 2026 | $-0.29 | $-0.52 | -82.1% | $6.1M |
| Tuesday, March 24, 2026 | Q4 2025 | $0.02 | $-0.01 | -149.0% | $10.1M |
| Thursday, November 13, 2025 | Q3 2025 | $0.00 | $0.03 | — | $10.5M |
| Thursday, August 14, 2025 | Q2 2025 | $0.33 | $-0.03 | -109.2% | $49.3M |
What the market is watching in BSEM's next report
- The full Earnings Read for this company: focus areas, peer read-through and prior-reaction context.
- Ticker Read combines trend, relative strength and catalysts in one research view.
- Scanners, Impact Radar and the members-only Weekly Watchlist are included.
Get the week's earnings by email
One free email each week: the reports that matter, when they land, and what the market is watching.
Frequently asked questions
- When is the next BSEM earnings date?
- Biostem Technologies Inc is scheduled to report on Wednesday, November 11, 2026 (Time TBD). Dates can change until the company confirms them.
- Does BSEM report before or after the market?
- The next report is scheduled time tbd.
- What EPS is expected for BSEM?
- Consensus EPS for the upcoming quarter is $-0.47, on revenue of $8.1M.
Calendar data is provided for educational and research purposes only and is not investment advice. Release dates, times, estimates and results can change; always verify against the issuing company or agency.
BSEM earnings discussion
Anyone can read. Any free Hyper Stocks account can join in.
Create a free account to join the discussion. Reading is open to everyone — commenting is free, no subscription needed.
Loading discussion…
Member comments are opinions from individual users, not Hyper Stocks research, and are never personalised investment advice.